Congress passes BioShield bill, but some talk about BioShield II

August 1, 2004

After almost two years of disputes and delay, the House overwhelmingly approved legislation last month to fund private-sector development of vaccines and countermeasures to biological and chemical warfare. The Project BioShield bill had passed the Senate last May and provides $5.6 billion over 5 years to purchase counter-terrorism therapies for national stockpiles.